SEC-sourced researchBeta

KNSA

Kiniksa Pharmaceuticals International, plc

US markets

Data passport

CIK: 0001730430
Exchange: Nasdaq
Business activity: — · SIC 2834
Financial inputs: 6/6
Filing date: Sep 3, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 11:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

KNSA · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	270,259,000.0000	Feb 24, 2026
December 2024	423,239,000.0000	Feb 24, 2026
December 2025	677,564,000.0000	Feb 24, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	677,564,000.0000	59,005,000.0000	137,985,000.0000	763,633,000.0000	196,027,000.0000	Feb 24, 2026
December 2024	423,239,000.0000	-43,193,000.0000	25,689,000.0000	580,553,000.0000	142,117,000.0000	Feb 24, 2026
December 2023	270,259,000.0000	14,084,000.0000	13,301,000.0000	—	—	Feb 24, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$677.56M	December 2025	Feb 24, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$423.24M	December 2024	Feb 24, 2026	10-K
Net incomeNetIncomeLoss	$59.01M	December 2025	Feb 24, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$137.99M	December 2025	Feb 24, 2026	10-K
Total assetsAssets	$763.63M	December 2025	Feb 24, 2026	10-K
Total liabilitiesLiabilities	$196.03M	December 2025	Feb 24, 2026	10-K

New filings

Explore methodology ↗